Mini review · 30 May 2023
Conference abstractPublished 7 Dec 2015
Replication competent viral vectors for vaccine development
GeoVax, Inc, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Viral infections account for 15 million deaths per year, one-third of all mortalities worldwide. The most effective medical approach to combat viral diseases and reduce deaths is vaccinations, which have less adverse side effects than drugs while inducing longer lasting protection from reinfection. Live attenuated, inactivated, or subunit vaccine approaches have been successfully utilized to combat mortalities caused by infectious diseases such as yellow fever, varicella, measles, mumps, rubella, influenza, smallpox, polio, rabies, hepatitis A and B, and human papillomavirus. Viruses themselves have also been used as vectors (either replication competent or replication deficient) for development of vaccines against both infectious and non-infectious diseases. The most important factor in the construction of effective viral vectors is finding the right balance between safety and immunogenicity. Although live viral vaccine vectors are highly efficacious, there is also a greater potential risk involved with their broader usage because they are replication-competent. Vaccines based on replication-incompetent viruses are perceived to be safer but there is not yet any vaccine on the market for human use. In this talk, characteristics of both replication-deficient and replication-competent viral vectors and barriers for their developments will be discussed. The talk will specifically focus on a few vector examples that have either generated marketed products or have successfully completed their phase 3 efficacy trials.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 7 Dec 2015
Engineering of Highly Efficient Recombinant Viral Vectors for Development of Prime-Boost Vaccines Against Viral Diseases
Short communication · 30 Sep 2024
Viral Vector-Based Vaccines: Current Trends and Future Prospects
Perspective · 16 May 2023
The Role of MAIT Cells in Immunogenicity of Viral Vector Vaccinations
Article · 2 Dec 2022
Herpes zoster involving the maxillary branch of the trigeminal nerve after viral vector covid19 vaccine is it a possible
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
How is really working adaptive immune system in mammals? A novel conception and reverse pathway theory, which will bring novel multibillion super-antibody (sab) technology for curing of all of infectious diseases and cancer!
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Farshad Guirakhoo”

